Trial Profile
Evaluation of the Clinical Response of Mitomycin-C (MMC) Embedded in Hydrogel (TC-3) in Comparison to Mitomycin C in Saline, When Administered Intravesically, Pre-TURBT in Non Muscle Invasive Bladder Cancer (NMIBC) Patients. Muscle Invasive Bladder Cancer (NMIBC) Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Sep 2016
Price :
$35
*
At a glance
- Drugs Mitomycin (Primary)
- Indications Bladder cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors UroGen Pharma
- 21 Sep 2016 New trial record